Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features

Tang,Caiyun; Gong,Lingqi; Zou,Wenli; Zhang,Jie; Zhou,Yuqian; Wu,Xiaoping; Lu,Fanggen; Ouyang,Chunhui; Liu,Xiaowei

doi:10.3892/or.2016.5170

Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features

Authors:
- Caiyun Tang
- Lingqi Gong
- Wenli Zou
- Jie Zhang
- Yuqian Zhou
- Xiaoping Wu
- Fanggen Lu
- Chunhui Ouyang
- Xiaowei Liu
View Affiliations

Affiliations: Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China
Published online on: October 13, 2016 https://doi.org/10.3892/or.2016.5170
Pages: 3343-3352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) are relatively uncommon. Unfortunately, epidemiological studies on the incidence of GEP‑NETs worldwide have reported a marked increase in the detection of these tumors. Although they often exhibit relatively indolent clinical courses, GEP‑NETs have the potential for lethal progression, especially in patients who present with advanced disease. Early detection and surgical removal is currently the only reliable curative treatment for GEP‑NET patients. The objective of this study was to analyze the clinicopathological characteristics of GEP‑NETs and explore the metastasis‑related risk factors of patients with GEP‑NETs. One hundred and forty‑six patients diagnosed pathologically with GEP‑NETs from January 2001 to January 2015 at the Second Xiangya Hospital of Central South University were retrospectively evaluated. We retrieved and analyzed information concerning clinical characteristics and metastasis‑related risk factors, and used Chi‑square test and logistic regression analysis to analyze the clinicopathological characteristics of GEP‑NETs and explore the association between tumor metastasis and possible related risk factors. The results revealed that the most common clinical manifestations were abdominal pain (n=88), alteration in the character of stool (n=58) and melaena (n=33). Rectum (91/146, 62.3%) and stomach (19/146, 13.0%) were the main sites of metastasis. Both Chi‑square test and logistic regression analysis showed that tumor size (P<0.05), tumor type (P=0.008) and peritumoral lymphatic vessel density (LVD) (P=0.004) were significantly correlated with tumor metastasis. Neither Chi‑square test nor logistic regression analysis indicated that gender (P>0.05), age (P>0.05), tumor location (P>0.05), tumor number (P>0.05), chromaffin granule protein A [chromogranin A (CgA), P>0.05], synaptophysin (Syn, P>0.05) or intratumoral LVD (P>0.05) had a significant correlation with tumor metastasis. Chi‑square test revealed that tumor grade was significantly correlated with tumor metastasis. In conclusion, GEP‑NETs may occur in multiple sites of the digestive system and lack specific clinical manifestations. Tumor size, tumor type, peritumoral LVD, total LVD and tumor grade are metastasis‑related risk factors for GEP‑NET patients.

View Figures

View References

1	Meeker A and Heaphy C: Gastroenteropancreatic endocrine tumors. Mol Cell Endocrinol. 386:101–120. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pinchot SN, Holen K, Sippel RS and Chen H: Carcinoid tumors. Oncologist. 13:1255–1269. 2008. View Article : Google Scholar : PubMed/NCBI
3	Strosberg JR, Nasir A, Hodul P and Kvols L: Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2:113–125. 2008.PubMed/NCBI
4	Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, et al: UK and Ireland Neuroendocrine Tumour Society: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 61:6–32. 2012. View Article : Google Scholar : PubMed/NCBI
5	Klöppel G, Rindi G, Anlauf M, Perren A and Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 451:(Suppl 1). S9–S27. 2007. View Article : Google Scholar : PubMed/NCBI
6	Richards-Taylor S, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T, Pearce N and Cave J: The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: A systematic review and meta-analysis. J Clin Pathol. 69:612–618. 2016. View Article : Google Scholar : PubMed/NCBI
7	Baudin E, Planchard D, Scoazec JY, Guigay J, Dromain C, Hadoux J, Debaere T, Elias D and Ducreux M: Intervention in gastro-enteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 26:855–865. 2012. View Article : Google Scholar : PubMed/NCBI
8	Knigge U and Hansen CP: Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol. 26:819–831. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li ZS and Li Q: The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 40:351–354. 2011.(In Chinese). PubMed/NCBI
10	Yang Z, Tang LH and Klimstra DS: Gastroenteropancreatic neuroendocrine neoplasms: Historical context and current issues. Semin Diagn Pathol. 30:186–196. 2013. View Article : Google Scholar : PubMed/NCBI
11	Capelli P, Fassan M and Scarpa A: Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol. 26:705–717. 2012. View Article : Google Scholar : PubMed/NCBI
12	Raica M, Cimpean AM and Ribatti D: The role of podoplanin in tumor progression and metastasis. Anticancer Res. 28:2997–3006. 2008.PubMed/NCBI
13	Gastrointestinal Pathology Study Group of Korean Society of Pathologists, ; Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, et al: Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: Multicenter study. Cancer Res Treat. 44:157–165. 2012. View Article : Google Scholar : PubMed/NCBI
14	Fraenkel M, Kim MK, Faggiano A and Valk GD: Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 26:691–703. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kuiper P, Verspaget HW, Overbeek LI, Biemond I and Lamers CB: An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: The diagnostic approach. Neth J Med. 69:14–20. 2011.PubMed/NCBI
16	Solcia E, Rindi G, Paolotti D, La Rosa S, Capella C and Fiocca R: Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol. 10:(Suppl 2). S9–S15. 1999. View Article : Google Scholar : PubMed/NCBI
17	Schott M, Klöppel G, Raffel A, Saleh A, Knoefel WT and Scherbaum WA: Neuroendocrine neoplasms of the gastrointestinal tract. Dtsch Arztebl Int. 108:305–312. 2011.PubMed/NCBI
18	Zhou X, Xie H, Xie L, Li J, Cao W and Fu W: Endoscopic resection therapies for rectal neuroendocrine tumors: A systematic review and meta-analysis. J Gastroenterol Hepatol. 29:259–268. 2014. View Article : Google Scholar : PubMed/NCBI
19	Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, et al: TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 449:395–401. 2006. View Article : Google Scholar : PubMed/NCBI
20	Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol A-M, Nilsson O, Perren A, Scarpa A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 451:757–762. 2007. View Article : Google Scholar : PubMed/NCBI
21	Tsuboi K, Shimura T, Suzuki H, Mochiki E, Haga N, Masuda N, Soda M, Yamamoto H, Asao T and Kuwano H: Liver metastases of a minute rectal carcinoid less than 5mm in diameter: A case report. Hepatogastroenterology. 51:1330–1332. 2004.PubMed/NCBI
22	Chun HJ, Jeen YT, Park SC, Keum B, Seo YS, Um SH, Kim CD and Ryu HS: Multiple liver metastases from a rectal carcinoid tumor. Gastrointest Endosc. 71:619–620. 2010. View Article : Google Scholar : PubMed/NCBI
23	Attili F, Capurso G, Vanella G, Fuccio L, Delle Fave G, Costamagna G and Larghi A: Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis. 46:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
24	De Angelis C, Brizzi RF and Pellicano R: Endoscopic ultrasonography for pancreatic cancer: Current and future perspectives. J Gastrointest Oncol. 4:220–230. 2013.PubMed/NCBI
25	Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC and Sun CF: Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 95:344–350. 2012. View Article : Google Scholar : PubMed/NCBI
26	Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N, et al: Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: A multicenter study developed in Argentina. Acta Gastroenterol Latinoam. 39:184–189. 2009.PubMed/NCBI
27	Gao W, Liu SM, Lu HZ, Liang J, Yuan YL and Liu XY: Analysis of clinicopathological features of intestinal neuroendocrine neoplasms. Zhonghua Zhong Liu Za Zhi. 34:450–456. 2012.(In Chinese). PubMed/NCBI
28	Li AF, Li AC, Hsu CY, Li WY, Hsu HS and Chen JY: Small cell carcinomas in gastrointestinal tract: Immunohistochemical and clinicopathological features. J Clin Pathol. 63:620–625. 2010. View Article : Google Scholar : PubMed/NCBI
29	Özaslan E, Demir S, Karaca H and Güven K: Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors. Eur J Gastroenterol Hepatol. 28:836–841. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Guo Y, Wang B, Bi J, Li K, Liang X, Chu H and Jiang H: Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: A systematic review and meta-analysis of the literature. Mol Biol Rep. 39:11153–11165. 2012. View Article : Google Scholar : PubMed/NCBI
31	Takahashi A, Ishii G, Kinoshita T, Yoshida T, Umemura S, Hishida T, Yoh K, Niho S, Goto K, Ohmatsu H, et al: Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung. J Cancer Res Clin Oncol. 139:1869–1878. 2013. View Article : Google Scholar : PubMed/NCBI
32	Watanabe M, Tanaka H, Ohira M, Yoshii M, Sakurai K, Toyokawa T, Kubo N, Yamamoto A, Muguruma K, Yamashita Y, et al: Intranodal lymphangiogenesis precedes development of lymph node metastasis and accelerates progression of gastric cancer. J Gastrointest Surg. 18:481–490. 2014. View Article : Google Scholar : PubMed/NCBI
33	Pasquali S, van der Ploeg AP, Mocellin S, Stretch JR, Thompson JF and Scolyer RA: Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res. 26:326–337. 2013. View Article : Google Scholar : PubMed/NCBI
34	Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY and Van Laere S: Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: Systematic review and meta-analysis. Br J Dermatol. 170:66–77. 2014. View Article : Google Scholar : PubMed/NCBI